Alemtuzumab for patients with chronic lymphocytic leukaemia

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 12, 2012, Pages

  Skoetz, Nicole ^a   Bauer, Kathrin ^a   Elter, Thomas ^a   Monsef, Ina ^a   Roloff, Verena ^b   Hallek, Michael ^a   Engert, Andreas ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b MRC BIOSTATISTICS UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CHLORAMBUCIL; FLUDARABINE; RITUXIMAB; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; VIDARABINE;

ANEMIA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEVER; FOLLOW UP; HUMAN; HYPOTENSION; INFUSION RELATED REACTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOPENIA; LYMPHOCYTOPENIA; MINIMAL RESIDUAL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SEPSIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; URTICARIA; VOMITING; META ANALYSIS; MORTALITY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CHLORAMBUCIL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VIDARABINE;

EID: 84861433065     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008078.pub2     Document Type: Review

References (88)

1. Demko S, Summers J, Keegan P, Pazdur R. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia. Oncologist 2008;13:167-74.
2. Dmoszynska A, Fetni R, Wang Y, Belkaci M, Sirard C, Goldberg M, et al. Cytogenetic correlation with efficacy on alemtuzumab (CAM) vs chlorambucil (CHLO) as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) [abstract]. Journal of Clinical Oncology 2006; Vol. 24:361.
3. Genzyme. A phase III study to evaluate the efficacy and safety of front-line therapy with alemtuzumab (Campath, MabCampath) vs chlorambucil in patients with progressive B-cell chronic lymphocytic leukemia (ClinicalTrials.gov identifier: NCT00046683). http://www.clinicaltrials.gov 2003.
4. Hillmen P, Skotnicki A, Robak T, Jaksic B, Dmoszynka A, Sirard C, et al. Preliminary phase III efficacy and safety of alemtuzumab vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) [abstract]. Journal of Clinical Oncology 2006; Vol. 24:339.
5. Hillmen P, Skotnicki A, Robak T, Jaksic B, Sirard C, Mayer J. Alemtuzumab (Campath, MabCampath) Has superior progression free survival (PFS) vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) [Abstract]. Blood 2006; Vol. 108:93.
6. Hillmen P, Skotnicki A, Robak T, Jaksic B, Sirard C, Mayer J. Progression free survival is superior with alemtuzumab vs chlorambucil as front-line therapy for patients with B-cell chronic lymphocytic leukemia [Abstract] 1996. Haematologica 2007;92:45-6.
7. Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology 2007;25:5616-23.
8. Hillmen P, Skotnicki AB, Robak T, Mayer J, Jaksic B, Vukovic V, et al. Preliminary safety and efficacy report of a randomized trial of alemtuzumab vs chlorambucil as front-line therapy in 297 patients with progressive B-cell chronic lymphocytic leukemia. Blood 2004; Vol. 104:687a.
9. Hillmen PH, Skotnicki AS, Robak TR, Jaksic BJ, Dmoszynska AD, Sirard CS, et al. Preliminary results for the phase III trial of alemtuzumab (Campath, MabCampath) vs chlorambucil as first-line treatment for B-cell chronic lymphocytic leukemia (B-cll) [Abstract]. Haematologica 2006;91:381.
10. Mayer J, Robak T, Skotnicki A, Jaksic B, Dmoszynka A, Sirard C, et al. Impact of prognostic factors on outcome in a phase III study comparing alemtuzumab to chlorambucil as first-line therapy for B-cell chronic lymphocytic leukemia (BCLL) [abstract]. Journal of Clinical Oncology 2007; Vol. 25:365.
11. Mayer J, Robak T, Skotnicki A, Jaksic B, Vukovic V, Weitman S. Interim safety summary of alemtuzumab (Campath, Mabcampath) vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia [abstract]. Hematology Journal 2004;5:28.
12. Robak T, Dmoszynska A, Fetni R, Wang Y, Belkacz M, Sirard C. Incidence of genomic aberrations and associated efficacy from a phase III study comparing alemtuzumab (Campath, MabCampath) vs chlorambucil as first line therapy for B-cell chronic lymphocytic leukemia (BCLL). Blood 2006; Vol. 108.
13. Robak T, Skotnicki A, Dmoszynka A, Hebert J, Wang Y, Belkaci M, et al. Cytogenic abnormalities and associated efficacy from a phase iii study comparing alemtuzumab vs. Chlorambucil as first line therapy for b-cell chronic leukemia [Abstract] 1997. Haematologica 2007;92:46.
14. Robak T, Skotnicki AB, Mayer J, Vukovic V, Weitman S. Interim safety summary of alemtuzumab vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) [abstract]. Journal of Clinical Oncology 2004; Vol. 22:571.
15. Skotnicki AB, Robak T, Mayer J, Craig A, Weitman S. Phase III study to evaluate the efficacy and safety of front-line therapy with alemtuzumab (Campath, MabCampath) vs. chlorambucil in patients with progressive B-cell chronic lymphocytic leukemia (CAM307). Blood 2003;102:439a.
16. Elter T, Gercheva-Kyuchukova L, Pylylpenko H, Robak T, Jaksic B, Rekhtman G, et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. The Lancet Oncology published online 2011 October 10 [Epub ahead of print]. [PUBMED: 21992852]
17. Engert A, Gercheva L, Pilipenko G, Robak T, Wu J, Barry A, et al. Fludarabine (Flu) plus alemtuzumab (FluCam) improves progression free survival versus fludarabine in previously treated chronic lymphocytic leukemia and demonstrates activity in high risk patients. Haematologica 2010;95:Suppl 2.
18. Engert A, Gercheva L, Pilipenko G, Robak T, Wu J, Sirard CA, et al. Overall survival advantage and acceptable safety profile with fludarabine in combination with alemtuzumab (FluCam) in previously treated patients with advanced stage chronic lymphocytic leukemia. Blood 2010;116:919.
19. Engert A, Gercheva L, Robak T, Galina P, Wu J, Sirard CA, et al. Improved progression-free survival (PFS) of alemtuzumab (Campath, MabCampath) plus fludarabine (Fludara) versus fludarabine alone as second-line treatment of patients with B-cell chronic lymphocytic leukemia: preliminary results from a phase III randomized trial. Blood 2009;114:537.
20. Lepretre S, Aurran T, Mahe B, Cazin B, Tournihlac O, Maisonneuve H, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine (F), cyclophosphamide (C) and MabCampath (Cam) (FCCam) in previously untreated patients (pts) with advanced B-chronic lymphocytic leukemia (B-CLL): experience on safety and efficacy within a randomised multicenter phase III trial of the French Cooperative Group on CLL and WM (FCGCLL/MW) and the "Groupe Ouest-Est d'Etudes Des Leucemies Aigues Et Autres Maladies Du Sang" (GOELAMS): CLL2007FMP (for fit medically patients). Blood 2009;114:538.
21. Remi L, Lepretre S, Arnoulet C, Baseggio L, Campos L, Chatelain B, et al. CLL2007FMP, a phase III randomized multicentric trial of the French Cooperative Group on CLL and WM (FCGCLL/MW) and the "Groupe Ouest-Est D'etudes Des Leucemies Aigues Et Autres Maladies Du Sang" (GOELAMS): immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) yields a significantly better response than fludarabine (F), cyclophosphamide (C) and MabCampath (Cam) (FCCam) in previously untreated B-chronic lymphocytic leukemia patients as evaluated by a sensitive 6 color flow cytometry MRD. Blood 2010;116:698.
22. Ritgen M, Schweighofer C, Fingerle-Rowson G, Eichhorst B, Busch R, Stilgenbauer S. Consolidation with alemtuzumab in first remission induces pronounced MRD reduction and clinical remissions update on a randomized phase III trial of the German CLL Study Group (GCLLSG). Blood 2004; Vol. 104:687a.
23. Schweighofer C, Ritgen M, Eichhorst B, Busch R, Kneba M, Hallek M, et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukemia (CLL) in first remission long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG) [abstract]. Blood 2006;108:14.
24. Schweighofer CD, Ritgen M, Eichhorst BF, Busch R, Abenhardt W, Kneba M, et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology 2009;144:95-8.
25. Schweighofer CD, Ritgen M, Fingerle-Rowson G, Eichhorst B, Busch R, Stilgenbauer S, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - update on a randomized phase III trial of the German CLL Study Group (GSLLSG). Onkologie 2004;27:28-9.
26. Wendtner CM, Ritgen M, Fingerle-Rowson G, Jaeger G, Campe H, Engert A, et al. High efficacy but considerable toxicity of campath-1H consolidation therapy in CLL patients responding to fludarabine - results of a randomized phase III trial [abstract]. Journal of Clinical Oncology 2003;22:579.
27. Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jaeger G. Consolidiation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Blood 2003;102:676.
28. Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jager G, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004;18:1093-101.
29. Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jager G, et al. High efficacy but considerable toxicity of Alemtuzumab (MabCampath) consolidation therapy in CLL patients responding to Fludarabine or Fludarabine/cyclophosphamide - results of a randomized phase III trial of the GCLLSG. Onkologie 2003;26:173.
30. Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jager G, et al. High efficacy but considerable toxicity of alemtuzumab (Campath-1H) consolidation therapy in CLL patients responding to fludarabine - results of a randomized phase III trial of the GCLLSG [abstract: 0610]. Haematologica 2003;88:Suppl.
31. Gribben J, Stephans K, Blossom M. Fludarabine and alemtuzumab versus fludarabine and rituximab in the treatment of relapsed B-cell chronic lymphocytic leukemia: Results from a phase II study [abstract]. Blood 2005;106:343.
32. Bolli N, Di Ianni M, Simonetti S, Cerroni L, Liso A, Falini B, et al. Treating two concurrent B-cell and T-cell lymphoid neoplasms with alemtuzumab monotherapy. Lancet Oncology 2004;5:64-5.
33. Byrd JC, Peterson BL, Rai KR, Hurd D, Hohl R, Perry MC, et al. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leukemia & Lymphoma 2009;50:1589-96.
34. Elter T, Kilp J, Borchmann P, Schulz H, Hallek M, Engert A. Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Haematologica 2009;94:150-2.
35. Faderl S, Ferrajoli A, Wierda W, O'Brien S, Lerner S, Keating M J. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence.[Erratum appears in Cancer. 2010 Aug 15;116(16):3982 Note: Dosage error in article text]. Cancer 2010;116:2360-5.
36. Hale G, Rebello P, Brettman LR, Fegan C, Kennedy B, Kimby E, et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004;104:948-55.
37. Karlsson C, Norin S, Kimby E, Sander B, Porwit Macdonald A, Nilsson B, et al. Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation. Leukemia 2006;20:2204-7.
38. Kennedy B, Forsyth PD, Smith GM, Rawstrom AC, Byrne J, Haynes A, et al. Campath - 1h therapy does not affect pbsc collection and engraftment in patients with CLL previously treated with fludarabine [abstract]. Hematology Journal 2000;1:201.
39. Lin TS, Donohue KA, Byrd FC, Lucas MS, Hoke EE, Bengtson EM, et al. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. Journal of Clinical Oncology 2010;28:4500-6.
40. Osterborg A, Fassas AS, Anagnostopoulos A, Dyer MJ, Catovsky D, Mellstedt H. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. British Journal of Haematology 1996;93:151-3.
41. Pettitt AR, Matutes E, Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 2006;20:1441-5.
42. Alemtuzumab + rituximab consolidation in CLL (NCT00771602). Ongoing study August 2008.
43. Low dose alemtuzumab for consolidation and maintenance of patients with B-cell CLL (NCT00336206). Ongoing study June 12, 2006.
44. Subcutaneous alemtuzumab (CAMPATH®, MabCampath®) in relapsed/refractory B-CLL. Ongoing study May 18, 2006.
45. CLL8: a randomised, phase III study to assess alemtuzumab consolidation therapy in patients with CLL who have responded to previous therapy (ISRCTN63375144). Ongoing study June 2008.
46. Fludarabine combined with either alemtuzumab or rituximab in treating patients with refractory or relapsed B-CLL (NCT00086775). Ongoing study July 2003.
47. A randomised phase III study in previously untreated patients with biological high-risk CLL: fludarabine and cyclophosphamide (FC) versus FC and low-dose alemtuzumab (ISRCTN25180151). Ongoing study December 2005.
48. SCH 727965 in patients with mantle cell lymphoma or B-CLL (study P04715AM2) (NCT00871546). Ongoing study March 2009.
49. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48(1):198-206.
50. Byrd JC, Peterson BL, Rai KR, Hurd D, Hohl R, Perry MC, et al. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leukemia and Lymphoma 2009;50:1589-96.
51. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. The New England Journal of Medicine 2005;352(8):804-15.
52. Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurology 2011;10(4):338-48.
53. Cortelezzi A, Pasquini MC, Gardellini A, Gianelli U, Bossi A, Reda G, et al. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia 2009;23:2027-33.
54. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2011.
55. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. The New England Journal of Medicine 2000;343(26):1910-6.
56. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107(3):885-91.
57. Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. Journal of Clinical Oncology 2005;23(28):7024-31.
58. Elter T, Vehreschild JJ, Gribben J, Cornely OA, Engert A, Hallek M. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Annals of Hematology 2009;88:121-32.
59. Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. Journal of Clinical Oncology 2007;25(7):793-8.
60. Flynn JM, Byrd JC. Have we forgotten the purpose of phase III studies?. Journal of Clinical Oncology 2007;25(35):5553-5.
61. Fraser G, Smith CA, Imrie K, Meyer R, Hematology Disease Site Group. Alemtuzumab in chronic lymphocytic leukemia: a clinical practice guideline. Program in Evidence-based Care. Evidence-based series. Vol. 6-16, Toronto (ON): Cancer Care Ontario (CCO): AHRQ - Agency for Healthcare Research + Quality, 2006.
62. Jan B, Andrew O, Holger S. GRADEpro. Version 3.2 for Windows. Cochrane IMS, 2008.
63. Hainsworth JD, Vazquez ER, Spigel DR, Raefsky E, Bearden JD, Saez RA, et al. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer 2008;112:1288-95.
64. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111(12):5446-56.
65. Hallek M, Fingerle-Rowson G, Fink A, Busch, R, Mayer J, Hensel M, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). ASH Conference Proceedings. 2008:abstract 325.
66. Higgins JPT, Deeks JJ. Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (March 2011). Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2011.
67. Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2011.
68. Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2011.
69. Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology 2007;25(35):5616-23.
70. Kaufman MS, Caramanica A, Janson D, Driscoll N, Johnson C, Kohn N, et al. Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia. Med Oncol 2011;28:532-8.
71. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99(10):3554-61.
72. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2011.
73. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology 2009;62(10):1006-12.
74. Moreton P, Kennedy B, Lucas G, Leach M, Rassam SM, Haynes A, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. Journal of Clinical Oncology 2005;23(13):2971-9.
75. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
76. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46(2):219-34.
77. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
78. Schnemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings tables'. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2011.
79. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2011.
80. Steurer M, Pall G, Richards S, Schwarzer G, Bohlius J, Greil R. Purine antagonists for chronic lymphocytic leukaemia. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD004270.pub2]
81. Stilgenbauer S, Zenz, T, Winkler D, Buhler A, Schlenk R, Groner S, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. Journal of Clinical Oncology 2009;27(24):3994-4001.
82. Thursky KA, Worth LJ, Seymour JF, Miles PH, Slavin MA. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. British Journal of Haematology 2006;132(1):3-12.
83. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
84. Weingart O, Elter T, Bauer K, Brillant C, Herbst C, Monsef I, et al. Monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD008079]
85. Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jager G, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004;18(6):1093-101.
86. Wierda WG, Kipps TJ, Keating MJ. Novel immune-based treatment strategies for chronic lymphocytic leukemia. Journal of Clinical Oncology 2005;23(26):6325-32.
87. Wierda W, O'Brien S, Faderl S, Ferrajoli A, Wang X, Do KA, et al. A retrospective comparison of three sequential groups of patients with recurrent/refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 2006;106(2):337-45.
88. Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Browning M, et al. Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer 2011;117:116-24.